An In Silico Analysis of the Binding Modes and Binding Affinities of Small Molecule Modulators of PDZ-Peptide Interactions

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Tiwari, Garima ^a   Mohanty, Debasisa ^a  

^a NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

PDZ PROTEIN; POSTSYNAPTIC DENSITY PROTEIN 95;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; BINDING KINETICS; BINDING MODE; CALCULATION; COMPUTER MODEL; CONTROLLED STUDY; LIGAND BINDING; MATHEMATICAL COMPUTING; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR MODEL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; SEQUENCE ANALYSIS; STRUCTURE ANALYSIS;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIGANDS; MEMBRANE PROTEINS; MOLECULAR DOCKING SIMULATION; MOLECULAR DYNAMICS SIMULATION; MOLECULAR SEQUENCE DATA; PDZ DOMAINS; PEPTIDES; PROTEIN BINDING; RATS; SMALL MOLECULE LIBRARIES;

EID: 84881332909     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071340     Document Type: Article

References (54)

1. te Velthuis AJ, Sakalis PA, Fowler DA, Bagowski CP, (2011) Genome-wide analysis of PDZ domain binding reveals inherent functional overlap within the PDZ interaction network. PLoS One 6: e16047.
2. Kim E, Niethammer M, Rothschild A, Jan YN, Sheng M, (1995) Clustering of Shaker-type K+ channels by interaction with a family of membrane-associated guanylate kinases. Nature 378: 85-88.
3. Kim E, Sheng M, (2004) PDZ domain proteins of synapses. Nat Rev Neurosci 5: 771-781.
4. Elias GM, Nicoll RA, (2007) Synaptic trafficking of glutamate receptors by MAGUK scaffolding proteins. Trends Cell Biol 17: 343-352.
5. Sheng M, Sala C, (2001) PDZ domains and the organization of supramolecular complexes. Annu Rev Neurosci 24: 1-29.
6. Gaudet S, Branton D, Lue RA, (2000) Characterization of PDZ-binding kinase, a mitotic kinase. Proc Natl Acad Sci U S A 97: 5167-5172.
7. Jeong KW, Kim HZ, Kim S, Kim YS, Choe J, (2007) Human papillomavirus type 16 E6 protein interacts with cystic fibrosis transmembrane regulator-associated ligand and promotes E6-associated protein-mediated ubiquitination and proteasomal degradation. Oncogene 26: 487-499.
8. Park JH, Lin ML, Nishidate T, Nakamura Y, Katagiri T, (2006) PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer. Cancer Res 66: 9186-9195.
9. Bossard F, Robay A, Toumaniantz G, Dahimene S, Becq F, et al. (2007) NHE-RF1 protein rescues DeltaF508-CFTR function. Am J Physiol Lung Cell Mol Physiol 292: L1085-1094.
10. Lee JH, Richter W, Namkung W, Kim KH, Kim E, et al. (2007) Dynamic regulation of cystic fibrosis transmembrane conductance regulator by competitive interactions of molecular adaptors. J Biol Chem 282: 10414-10422.
11. Dev KK, Henley JM, (2006) The schizophrenic faces of PICK1. Trends Pharmacol Sci 27: 574-579.
12. Fallon L, Moreau F, Croft BG, Labib N, Gu WJ, et al. (2002) Parkin and CASK/LIN-2 associate via a PDZ-mediated interaction and are co-localized in lipid rafts and postsynaptic densities in brain. J Biol Chem 277: 486-491.
13. Songyang Z, Fanning AS, Fu C, Xu J, Marfatia SM, et al. (1997) Recognition of unique carboxyl-terminal motifs by distinct PDZ domains. Science 275: 73-77.
14. Aarts M, Liu Y, Liu L, Besshoh S, Arundine M, et al. (2002) Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions. Science 298: 846-850.
15. Deval E, Salinas M, Baron A, Lingueglia E, Lazdunski M, (2004) ASIC2b-dependent regulation of ASIC3, an essential acid-sensing ion channel subunit in sensory neurons via the partner protein PICK-1. J Biol Chem 279: 19531-19539.
16. Pichon X, Wattiez AS, Becamel C, Ehrlich I, Bockaert J, et al. (2010) Disrupting 5-HT(2A) receptor/PDZ protein interactions reduces hyperalgesia and enhances SSRI efficacy in neuropathic pain. Mol Ther 18: 1462-1470.
17. Dev KK, (2004) Making protein interactions druggable: targeting PDZ domains. Nat Rev Drug Discov 3: 1047-1056.
18. Wen W, Wang W, Zhang M, (2006) Targeting PDZ domain proteins for treating NMDA receptor-mediated excitotoxicity. Curr Top Med Chem 6: 711-721.
19. Wang NX, Lee HJ, Zheng JJ, (2008) Therapeutic use of PDZ protein-protein interaction antagonism. Drug News Perspect 21: 137-141.
20. LeBlanc BW, Iwata M, Mallon AP, Rupasinghe CN, Goebel DJ, et al. (2010) A cyclic peptide targeted against PSD-95 blocks central sensitization and attenuates thermal hyperalgesia. Neuroscience 167: 490-500.
21. You L, Xu Z, Punchihewa C, Jablons DM, Fujii N, (2008) Evaluation of a chemical library of small-molecule Dishevelled antagonists that suppress tumor growth by down-regulating T-cell factor-mediated transcription. Mol Cancer Ther 7: 1633-1638.
22. Grandy D, Shan J, Zhang X, Rao S, Akunuru S, et al. (2009) Discovery and characterization of a small molecule inhibitor of the PDZ domain of dishevelled. J Biol Chem 284: 16256-16263.
23. Bach A, Stuhr-Hansen N, Thorsen TS, Bork N, Moreira IS, et al. (2010) Structure-activity relationships of a small-molecule inhibitor of the PDZ domain of PICK1. Org Biomol Chem 8: 4281-4288.
24. Hammond MC, Harris BZ, Lim WA, Bartlett PA, (2006) Beta strand peptidomimetics as potent PDZ domain ligands. Chem Biol 13: 1247-1251.
25. Piserchio A, Salinas GD, Li T, Marshall J, Spaller MR, et al. (2004) Targeting specific PDZ domains of PSD-95; structural basis for enhanced affinity and enzymatic stability of a cyclic peptide. Chem Biol 11: 469-473.
26. Udugamasooriya DG, Sharma SC, Spaller MR, (2008) A chemical library approach to organic-modified peptide ligands for PDZ domain proteins: a synthetic, thermodynamic and structural investigation. Chembiochem 9: 1587-1589.
27. Bach A, Chi CN, Olsen TB, Pedersen SW, Roder MU, et al. (2008) Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. J Med Chem 51: 6450-6459.
28. Fujii N, Shelat A, Hall RA, Guy RK, (2007) Design of a selective chemical probe for class I PDZ domains. Bioorg Med Chem Lett 17: 546-548.
29. Bach A, Eildal JN, Stuhr-Hansen N, Deeskamp R, Gottschalk M, et al. (2011) Cell-permeable and plasma-stable peptidomimetic inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. J Med Chem 54: 1333-1346.
30. Wang Y, Xiao J, Suzek TO, Zhang J, Wang J, et al. (2009) PubChem: a public information system for analyzing bioactivities of small molecules. Nucleic Acids Res 37: W623-633.
31. ChemDraw CC, 875 Massachusetts Ave., Cambridge M, USA., http://www.camsoft.com/.Accessed 2011 August 25.
32. http://www.R-project.org RCT (2013) R: A Language and Environment for Statistical Computing. R Foundation for statistical computing, Vienna, Austria. Accessed 2013 January 28.
33. http://www.openbabel.org (2011) The Open Babel Package, version 2.3.1. Accessed 2011 February 10.
34. O'Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, et al. (2011) Open Babel: An open chemical toolbox. J Cheminform 3: 33.
35. Trott O, Olson AJ, (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31: 455-461.
36. Tochio H, Hung F, Li M, Bredt DS, Zhang M, (2000) Solution structure and backbone dynamics of the second PDZ domain of postsynaptic density-95. J Mol Biol 295: 225-237.
37. Doyle DA, Lee A, Lewis J, Kim E, Sheng M, et al. (1996) Crystal structures of a complexed and peptide-free membrane protein-binding domain: molecular basis of peptide recognition by PDZ. Cell 85: 1067-1076.
38. Nocedal J, Wright SJ (1999) Numerical Optimization; Springer Verlag:Berlin. Springer Series in Operations Research.
39. Case DA, Darden TA, Cheatham TEI, Simmerling CL, Wang J, et al. (2006) AMBER 9. Universiy of California, San Francisco.
40. Duan Y, Wu C, Chowdhury S, Lee MC, Xiong G, et al. (2003) A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. J Comput Chem 24: 1999-2012.
41. Wang J, Wang W, Kollman PA, Case DA, (2006) Automatic atom type and bond type perception in molecular mechanical calculations. J Mol Graph Model 25: 247-260.
42. Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA, (2004) Development and testing of a general amber force field. J Comput Chem 25: 1157-1174.
43. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML, (1983) Comparison of simple potential functions for simulating liquid water. J Chem Phys 79: 10.
44. Darden T, York D, Pedersen L (1993) Particle mesh Ewald: An N{dot operator}log(N) method for Ewald sums in large systems. J Chem Phys: 10089-10092.
45. Kollman PA, Massova I, Reyes C, Kuhn B, Huo S, et al. (2000) Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res 33: 889-897.
46. Thorsen TS, Madsen KL, Rebola N, Rathje M, Anggono V, et al. (2010) Identification of a small-molecule inhibitor of the PICK1 PDZ domain that inhibits hippocampal LTP and LTD. Proc Natl Acad Sci U S A 107: 413-418.
47. Shan J, Zhang X, Bao J, Cassell R, Zheng JJ, (2012) Synthesis of potent dishevelled PDZ domain inhibitors guided by virtual screening and NMR studies. Chem Biol Drug Des 79: 376-383.
48. Saupe J, Roske Y, Schillinger C, Kamdem N, Radetzki S, et al. (2011) Discovery, structure-activity relationship studies, and crystal structure of nonpeptide inhibitors bound to the Shank3 PDZ domain. ChemMedChem 6: 1411-1422.
49. Vogrig A, Boucherle B, Deokar H, Thomas I, Ripoche I, et al. (2011) NMR evaluation of interactions between substituted-indole and PDZ1 domain of PSD-95. Bioorg Med Chem Lett 21: 3349-3353.
50. Boucherle B, Vogrig A, Deokar H, Bouzidi N, Ripoche I, et al. (2011) Synthesis and evaluation of bidentate ligands designed to interact with PDZ domains. Bioorg Med Chem 19: 4346-4354.
51. Fujii N, Haresco JJ, Novak KA, Gage RM, Pedemonte N, et al. (2007) Rational design of a nonpeptide general chemical scaffold for reversible inhibition of PDZ domain interactions. Bioorg Med Chem Lett 17: 549-552.
52. Mayasundari A, Ferreira AM, He L, Mahindroo N, Bashford D, et al. (2008) Rational design of the first small-molecule antagonists of NHERF1/EBP50 PDZ domains. Bioorg Med Chem Lett 18: 942-945.
53. Fujii N, You L, Xu Z, Uematsu K, Shan J, et al. (2007) An antagonist of dishevelled protein-protein interaction suppresses beta-catenin-dependent tumor cell growth. Cancer Res 67: 573-579.
54. Shan J, Zheng JJ, (2009) Optimizing Dvl PDZ domain inhibitor by exploring chemical space. J Comput Aided Mol Des 23: 37-47.